Exact Sciences’ next-generation Cologuard stool-based test for colorectal cancer demonstrated 94% sensitivity and 91% specificity in its latest study, according to the company.
The results will be 510(k) application to the US Food and Drug Administration later this year. The FDA approved the
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?